Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 9, 2009, Pages 558-563

  Łukaszewicz Zaja̧c, Marta ^a   Mroczko, Barbara ^a   Kozłowski, Mirosław ^a   Nikliński, Jacek ^a   Laudański, Jerzy ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Esophageal squamous cell carcinoma; Matrix metalloproteinase 9

Indexed keywords

METALLOPROTEINASE; METALLOPROTEINASE 9; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METALLOPROTEINASE 9 BLOOD LEVEL;

EID: 70349869232     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.765     Document Type: Article

References (22)

1. Kuwano H, Nakajima M, Miyazaki T, et al. Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma. Ann Thorac Cardiovasc Surg. 2003; 9: 6-13. (Pubitemid 36091471)
2. Ohashi K, Nemoto T, Nakamura K, et al. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer. 2000; 88: 2201-2209. (Pubitemid 30247118)
3. Samantaray S, Sharma R, Chattopadhyaya TK, et al. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004; 130: 37-44. (Pubitemid 38161246)
4. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation. 2002; 70: 561-573. (Pubitemid 36194320)
5. Kabashima A, Maehara Y Kakeji Y, et al. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res. 2000; 6: 3581-3584. (Pubitemid 30694940)
6. Gu ZD, Li JY, Li M, et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 2005; 100: 1835-1843. (Pubitemid 41648441)
7. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer is it worth talking about? Cancer Metastasis Rev. 2004; 23: 119-135.
8. de Mingo M, Morán A, Sánchez-Pernaute A, et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology. 2007; 54: 315-319.
9. Yang X, Staren ED, Howard JM, et al. Invasiveness and MMP Expression in Pancreatic Carcinoma. J Surg Res. 2001; 98: 33-39. (Pubitemid 32493624)
10. Gu ZD, Chen KN, Li M, et al. Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol. 2005; 11: 871-874. (Pubitemid 40298091)
11. Jass JR, Sobin LH. WHO International Histological Classification of Tumors. Histological Typing of Intestinal Tumors. New York, Springer-Verlag, 1989.
12. Fisher LD, van Belle G. Biostatististics: a methodology for the health science. New York, John Wiley and Sons, 1993.
13. Messmann H. Squamous cell cancer of the oesophagus. Best Pract Res Clin Gastroenterol. 2001; 15: 249-265.
14. Ylisimio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-2, -9 and tissue inhibitors of metalloproteinase-1, -2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res. 2000; 20: 1311-1316. (Pubitemid 30240720)
15. Shen KH, Chi CW, Lo SS, et al. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res. 2000; 20: 1307-1310.
16. Oberg A, Hoyhtya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000; 20: 1085-1091. (Pubitemid 30240680)
17. Murawaki Y, Ikuta Y, Okamoto K, et al. Plasma matrix metalloproteinase-9 (gelatinase B) in patients with hepatocellular carcinoma. Res Commun Mol Pathol Pharmacol. 2000; 108: 351-357.
18. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer. 2005; 116: 422-427. (Pubitemid 40993339)
19. Mroczko B, Kozłowski M, Groblewska M, et al. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2008; 389: 61-66.
20. El-Shahat M, Lotfy M, Fahmy L, et al. Prognostic value of microvessel density, matrix metalloproteinase-9 and p53 protein expression in esophageal cancer. J Egypt Natl Cancer Inst. 2004; 16: 224-230.
21. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002; 29: 78-86. (Pubitemid 34226522)
22. Chen W, Abnet CC, Wei WQ, et al. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res. 2004; 24: 3245-3249. (Pubitemid 39390980)